Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Zealand Pharma. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Zealand Pharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
Zealand Pharma's earnings are expected to grow by 6.4% yearly, however this is not considered high growth (20% yearly).
Zealand Pharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Zealand Pharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
4/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Emmanuel Dulac, PharmD, PhD, MBA, has been Chief Executive Officer at Zealand Pharma A/S since April 22, 2019 and its President since 2019. He had been Chief Commercial Officer and Senior Vice President of Alnylam Pharmaceuticals, Inc. from September 19, 2016 to June 2018 and its Chief International Strategy since August 2016. Dr. Dulac has more than 20 years of international experience in the biotech and pharmaceutical industry. He joined Alnylam Pharmaceuticals, from Shire, where he was Senior Vice President, Global Head of the Rare Disease Business Unit and General Manager of United States Operations from June 2014 to August 2016. Dr. Dulac held several leadership roles of increasing responsibility at Novartis (NYSE:NVS) from February 2006 to May 2014, including Vice President, Global Head Lung/Cystic Fibrosis. From August 2003 to February 2006, he was Business Unit Lead for Cardiovascular Medicine at Abbott (NYSE:ABT). Dr. Dulac held several roles of increasing responsibility at Sanofi (NASDAQ:SNY) from October 1994 to August 2003, including Associate Director. During his career, he successfully launched six brands, led two blockbuster drugs globally and built large sales organizations, innovative patient services and strong marketing and market access teams. He has been a Director of Proteostasis Therapeutics, Inc. since February 5, 2019. He graduated from the University of Paris XI with a Doctorate in Pharmacology (PharmD, Ph.D.) and completed an MBA from the ESSEC School in Paris.
Insufficient data for Emmanuel to compare compensation growth.
Insufficient data for Emmanuel to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Zealand Pharma management team is less than 2 years, this suggests a new team.
Senior Project Director
CEO & President
Interim CFO and Senior VP of Technical Development & Operations
Executive VP & Chief Science Officer
Investor Relations & Communications Officer
Head of Legal Affairs
Senior Vice President of Corporate & Business Development
Head of Bioanalysis
Head of Molecular Pharmacology
Executive VP and Chief Medical & Development Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Zealand Pharma board of directors is about average.
Board of Directors
Chairman of the Board
Senior Project Director
Co-Chair of the Clinical & Scientific Advisory Board & Director
Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide based medicines in Denmark. It has a portfolio of medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes glepaglutide, a long acting GLP-2 analog, which is in Phase 3 clinical trials for the treatment of short bowel syndrome; and dasiglucagon, a stable glucagon analog for the treatment of severe hypoglycemia in diabetes and congenital hyperinsulinism, as well as for use in dual-hormone automated pump therapy for management of type 1 diabetes. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; and Beta Bionics, Inc. to initiate home-use trial of the iLet bionic pancreas with dasiglucagon for autonomous bihormonal treatment of type 1 diabetes. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.